<DOC>
	<DOCNO>NCT00946140</DOCNO>
	<brief_summary>The purpose study develop new image analysis method use Dynamic Contrast Enhanced Magnetic Resonance Imaging ( DCE-MRI ) ovarian cancer . MRI currently part standard care ovarian cancer . In method , contrast agent use make ovarian cancer visible imaging .</brief_summary>
	<brief_title>Motion Correction Dynamic Contrast Enhanced Magnetic Resonance Imaging ( MRI ) Ovarian Cancer : A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Patients measurable disease evidence least one unidimensionally measurable tumor ( &gt; 1 cm ) CT MRI scan accord RECIST ( Response Evaluation Criteria Solid Tumors ) tumor initially treat surgery radiation therapy . Patients start treatment bevacizumab combine without cytotoxic chemotherapy within 14 day sign consent . Patients treat approved IRB therapeutic protocol recurrent ovarian cancer bevacizumab eligible . Patients histologically confirm ovarian epithelial cancer include primary peritoneal fallopian tube adenocarcinoma . Patients childbearing potential must negative serum pregnancy test prior study entry practice effective form contraception . Patients older 21 year age . Patients able understand sign inform consent . Patients treat approved IRB therapeutic protocol blind arm bevacizumab placebo eligible ( IRB 07078 IRB 05138 ) . Patients cardiac pacemaker . Patients certain prosthetic device implant compatible high magnetic field present DCEMRI scanner . Patients experience prior adverse reaction gadolinium complex contrast agent use DCEMRI image n't meet criterion creatinine nephrogenic systemic sclerosis risk per guideline department radiology . Patients prone claustrophobia . Patients dialysis .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Ovary</keyword>
	<keyword>MRI</keyword>
	<keyword>08-132</keyword>
</DOC>